Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

被引:123
作者
Koo, HM
VanBrocklin, M
McWilliams, MJ
Leppla, SH
Duesbery, NS
Vande Woude, GF
机构
[1] Van Andel Res Inst, Grand Rapids, MI 49503 USA
[2] Natl Canc Inst, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, Ft Detrick, MD 21702 USA
[3] Natl Inst Dental Res, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1073/pnas.052707699
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lethal factor, the principal virulence factor of Bacillus anthracis, inhibits mitogen-activated protein kinase (MAPK) signaling by proteolytically cleaving MAPK kinases. Edema factor, another component of anthrax toxin, is an adenylate cyclase, which increases intracellular cAMP. Inhibition of MAPK signaling with either anthrax lethal toxin (LeTx) or small molecule MAPK kinase inhibitors triggers apoptosis in human melanoma cells. Normal melanocytes do not undergo apoptosis in response to MAPK inhibition but arrest in the G, phase of the cell cycle. importantly, in vivo treatment of human melanoma xenograft tumors in athymic nude mice with LeTx results in significant or complete tumor regression without apparent side effects, suggesting that inhibiting the MAPK signaling pathway may be a useful strategy for treating melanoma. Additionally, interrupting MAPK signaling with LeTx and elevating cAMP with anthrax edema toxin in both melanoma cells and melanocytes lead to dramatic melanin production, perhaps explaining the formation of blackened eschars in cutaneous anthrax.
引用
收藏
页码:3052 / 3057
页数:6
相关论文
共 30 条
[1]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[2]  
BODART JF, 2002, IN PRESS CELL CYCLE
[3]   The development and therapeutic potential of protein kinase inhibitors [J].
Cohen, P .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) :459-465
[4]   A SYNTHETIC INHIBITOR OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE [J].
DUDLEY, DT ;
PANG, L ;
DECKER, SJ ;
BRIDGES, AJ ;
SALTIEL, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7686-7689
[5]   Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor [J].
Duesbery, NS ;
Webb, CP ;
Leppla, SH ;
Gordon, VM ;
Klimpel, KR ;
Copeland, TD ;
Ahn, NG ;
Oskarsson, MK ;
Fukasawa, K ;
Paull, KD ;
Vande Woude, GF .
SCIENCE, 1998, 280 (5364) :734-737
[6]   Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways [J].
Duesbery, NS ;
Resau, J ;
Webb, CP ;
Koochekpour, S ;
Koo, HM ;
Leppla, SH ;
Woude, GFV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :4089-4094
[7]   Anthrax toxins [J].
Duesbery, NS ;
Vande Woude, GF .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (12) :1599-1609
[8]   Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation [J].
Englaro, W ;
Bertolotto, C ;
Buscà, R ;
Brunet, A ;
Pagès, G ;
Ortonne, JP ;
Ballotti, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9966-9970
[9]   New insights into the control of MAP kinase pathways [J].
English, J ;
Pearson, G ;
Wilsbacher, J ;
Swantek, J ;
Karandikar, M ;
Xu, SC ;
Cobb, MH .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :255-270
[10]   Identification of a novel inhibitor of mitogen-activated protein kinase kinase [J].
Favata, MF ;
Horiuchi, KY ;
Manos, EJ ;
Daulerio, AJ ;
Stradley, DA ;
Feeser, WS ;
Van Dyk, DE ;
Pitts, WJ ;
Earl, RA ;
Hobbs, F ;
Copeland, RA ;
Magolda, RL ;
Scherle, PA ;
Trzaskos, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (29) :18623-18632